Moderna, Inc. (MRNA) stock experienced a significant pre-market decline of 5.1% following an analyst price target revision. The pre-market plunge occurred on Thursday, March 6th, 2025.
According to reports, Berenberg analysts adjusted their price target for Moderna down to $30 from the previous target of $33. The analysts maintained their "Hold" rating on the stock, reflecting a cautious outlook.
The downward revision of the price target by Berenberg analysts appears to have contributed to the pre-market sell-off in Moderna's shares. Investors reacted negatively to the reduced price expectations, as reflected in the stock's 5.1% drop during the pre-market trading session.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。